CN111116652A - A kind of preparation method of high-purity tedizolid phosphate - Google Patents
A kind of preparation method of high-purity tedizolid phosphate Download PDFInfo
- Publication number
- CN111116652A CN111116652A CN201911241003.3A CN201911241003A CN111116652A CN 111116652 A CN111116652 A CN 111116652A CN 201911241003 A CN201911241003 A CN 201911241003A CN 111116652 A CN111116652 A CN 111116652A
- Authority
- CN
- China
- Prior art keywords
- filter cake
- quality
- parts
- purified water
- reactor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QCGUSIANLFXSGE-GFCCVEGCSA-N tedizolid phosphate Chemical compound CN1N=NC(C=2N=CC(=CC=2)C=2C(=CC(=CC=2)N2C(O[C@@H](COP(O)(O)=O)C2)=O)F)=N1 QCGUSIANLFXSGE-GFCCVEGCSA-N 0.000 title claims abstract description 51
- 229960003947 tedizolid phosphate Drugs 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 25
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims abstract description 20
- BMQDAIUNAGXSKR-UHFFFAOYSA-N (3-hydroxy-2,3-dimethylbutan-2-yl)oxyboronic acid Chemical compound CC(C)(O)C(C)(C)OB(O)O BMQDAIUNAGXSKR-UHFFFAOYSA-N 0.000 claims abstract description 12
- QEYKDJZSXVVFSH-CYBMUJFWSA-N [(5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)pyridin-3-yl]phenyl]-1,3-oxazolidin-5-yl]methanol Chemical compound CN1N=C(N=N1)C1=NC=C(C=C1)C1=C(C=C(C=C1)N1CO[C@H](C1)CO)F QEYKDJZSXVVFSH-CYBMUJFWSA-N 0.000 claims abstract description 10
- JANKGNBDRWYWSN-UHFFFAOYSA-N 5-bromo-2-(2-methyltetrazol-5-yl)pyridine Chemical compound CN1N=NC(C=2N=CC(Br)=CC=2)=N1 JANKGNBDRWYWSN-UHFFFAOYSA-N 0.000 claims abstract description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims abstract description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000000463 material Substances 0.000 claims abstract 2
- 239000012065 filter cake Substances 0.000 claims description 100
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 75
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 47
- 238000003756 stirring Methods 0.000 claims description 47
- 239000008213 purified water Substances 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 37
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 27
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 23
- 238000001914 filtration Methods 0.000 claims description 23
- 238000002386 leaching Methods 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- 239000000706 filtrate Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 239000011259 mixed solution Substances 0.000 claims description 15
- 238000010438 heat treatment Methods 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 14
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 11
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 7
- UGBKYDASQNOIHP-SSDOTTSWSA-N (5r)-3-(4-bromo-3-fluorophenyl)-5-(hydroxymethyl)-1,3-oxazolidin-2-one Chemical compound O=C1O[C@@H](CO)CN1C1=CC=C(Br)C(F)=C1 UGBKYDASQNOIHP-SSDOTTSWSA-N 0.000 claims description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 6
- 235000011056 potassium acetate Nutrition 0.000 claims description 5
- 239000004201 L-cysteine Substances 0.000 claims description 3
- 235000013878 L-cysteine Nutrition 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 claims 2
- 150000000190 1,4-diols Chemical class 0.000 claims 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims 1
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 claims 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims 1
- SBYAVOHNDJTVPA-UHFFFAOYSA-N Isocarbamid Chemical compound CC(C)CNC(=O)N1CCNC1=O SBYAVOHNDJTVPA-UHFFFAOYSA-N 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 12
- UNXISIRQWPTTSN-UHFFFAOYSA-N boron;2,3-dimethylbutane-2,3-diol Chemical compound [B].[B].CC(C)(O)C(C)(C)O UNXISIRQWPTTSN-UHFFFAOYSA-N 0.000 abstract description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract description 4
- 229910052794 bromium Inorganic materials 0.000 abstract description 4
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 abstract description 3
- -1 4-bromo-3-fluorophenyl Chemical group 0.000 abstract description 2
- 239000003054 catalyst Substances 0.000 abstract description 2
- 230000026731 phosphorylation Effects 0.000 abstract description 2
- 238000006366 phosphorylation reaction Methods 0.000 abstract description 2
- 238000006555 catalytic reaction Methods 0.000 abstract 1
- 238000001816 cooling Methods 0.000 description 16
- 238000005406 washing Methods 0.000 description 5
- 239000012295 chemical reaction liquid Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- 231100000086 high toxicity Toxicity 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- ANPWLBTUUNFQIO-UHFFFAOYSA-N n-bis(phenylmethoxy)phosphanyl-n-propan-2-ylpropan-2-amine Chemical compound C=1C=CC=CC=1COP(N(C(C)C)C(C)C)OCC1=CC=CC=C1 ANPWLBTUUNFQIO-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003879 tedizolid Drugs 0.000 description 1
- XFALPSLJIHVRKE-GFCCVEGCSA-N tedizolid Chemical compound CN1N=NC(C=2N=CC(=CC=2)C=2C(=CC(=CC=2)N2C(O[C@@H](CO)C2)=O)F)=N1 XFALPSLJIHVRKE-GFCCVEGCSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A preparation method of high-purity tedizolid phosphate comprises the following steps: the method comprises the following steps: taking 2-methyl-5- (5-bromopyridine-2-yl) tetrazole as an initial material, taking tetrakis (triphenylphosphine) palladium (Pd (PPh3) 4) as a catalyst, and reacting with pinacol diboron to generate bromine of a compound shown in a formula 1, and converting the bromine into pinacol borate; step two: the compound of formula 3 is coupled with (5R) -3- (4-bromo-3-fluorophenyl) -5-hydroxymethyl oxazolidine-2-ketone by Suzuki under the catalysis of tetrakis (triphenylphosphine) palladium (Pd (PPh3) 4) to obtain (R) -3- [4- [2- (2-methyltetrazol-5-yl) pyridin-5-yl ] -3-fluorophenyl ] -5-hydroxymethyl oxazolidine; step three: the compound of the formula 5 is prepared under the condition of the phosphorylation of phosphorus oxychloride to obtain tedizolid phosphate.
Description
Technical Field
The invention belongs to the field of preparation of tedizolid phosphate, and particularly relates to a preparation method of high-purity tedizolid phosphate.
Background
Tedizolid phosphate (1) with the chemical name (R) -3- [4- [2- (2-methyltetrazol-5-yl) pyridin-5-yl]-3-fluorophenyl group]-5-hydroxyMethyl oxazolidin-2-one phosphate ester with the structureThe drug is a prodrug of a novel oxazolidinone antibacterial drug developed by Cubist pharmaceutical company, is approved by FDA to be on the market in 7 months in 2014, and has two administration modes of oral administration and injection. The product can be used for treating acute bacterial skin and skin tissue structure infection caused by gram-positive bacteria in vivo by removing phosphate group through serum phosphatase action and converting into active form tedizolid. Unlike chloramphenicol and lincomycin, the product does not hinder the formation of formylmethionine tRNA and is not easy to generate cross drug resistance with other drugs.
Because of the existing process steps of using high-toxicity organic tin reagent in the currently reported synthesis process of tedizolid phosphate; some process steps are used under the condition of ultralow temperature (-78 ℃), the reaction conditions are harsh, the yield is low due to more by-products in product quality, the purity is generally low below 70%, and the purity of the tedizolid phosphate obtained after the reaction is generally lower than 95%. In addition, a new process is reported in a document (a new synthesis method of tedizolid phosphate [ J ] application chemistry 2015 32 volume 11 period), wherein (5R) -3- (4-bromo-3-fluorophenyl) -5-hydroxymethyl oxazolidine-2-ketone (a compound shown in a formula 4) is used as a starting material, boronized, coupled with 2-methyl-5- (5-bromopyridin-2-yl) tetrazole (a compound shown in a formula 1) Suzuki, finally subjected to dibenzyl N, N-diisopropylphosphoramidite serving as a phosphorylation reagent, and finally subjected to debenzylation to obtain the tedizolid phosphate; the method finally removes benzyl through hydrogenation reaction, and has great potential safety hazard.
Disclosure of Invention
The invention provides a preparation method of high-purity tedizolid phosphate, which is used for overcoming the defects in the prior art.
The invention is realized by the following technical scheme:
a preparation method of high-purity tedizolid phosphate comprises the following steps:
the method comprises the following steps: adding 2-methyl-5- (5-bromopyridine-2-yl) tetrazole, pinacol diboron, potassium acetate and 1, 4-dioxane into a reactor, starting stirring, replacing with nitrogen twice, adding palladium tetrakis (triphenylphosphine) under the protection of nitrogen, heating to 65-75 ℃, reacting for 4 hours, stopping heating after the reaction is finished, adding n-heptane, cooling to 0-10 ℃, keeping the temperature and stirring for 1 hour, removing the protection of nitrogen, discharging and filtering, leaching a filter cake once with n-heptane, leaching until no filtrate drips, collecting the filter cake, drying at 45-55 ℃ in a vacuum drying oven, collecting and weighing after 8 hours to obtain pinacol borate;
step two:
step 1: adding pinacol borate, (5R) -3- (4-bromo-3-fluorophenyl) -5-hydroxymethyl oxazolidine-2-one, 1, 4-dioxane and a potassium carbonate solution into a reactor, starting stirring, replacing twice with nitrogen, adding tetrakis (triphenylphosphine) palladium under the protection of nitrogen, heating to 55-65 ℃, reacting for 5 hours, removing nitrogen after the reaction is finished, cooling to 20-30 ℃, adding purified water, cooling to 5-15 ℃, keeping the temperature and stirring for 0.5 hour, performing throw filtration, leaching a filter cake for 1 time by using 1, 4-dioxane, performing throw filtration until no liquid flows out, and collecting the filter cake;
step 2: adding the filter cake obtained in the step (1) and N, N-dimethylacetamide into a reactor, starting stirring, heating to 55-65 ℃, keeping the temperature and stirring for 1h, cooling to 15-25 ℃, filtering, leaching the filter cake with N, N-dimethylacetamide, and collecting filtrate;
and step 3: adding the filtrate obtained in the step 2, L-cysteine and triethylamine into a reactor, starting stirring, reacting in a dark place, replacing with nitrogen once, heating to 55-65 ℃, reacting for 16h, cooling to 15-25 ℃, reacting for 0.5h, performing suction filtration, leaching a filter cake for 1 time by using N, N-dimethylacetamide, and collecting filtrate;
and 4, step 4: adding the filtrate obtained in the step 3 into a reactor, starting stirring, cooling to 5-15 ℃, adding purified water, controlling the temperature below 35 ℃ in the process of adding the purified water, stirring for 1h at the temperature of 15-25 ℃ after adding the purified water, performing throw filtration, leaching filter cakes respectively for 1 time by using an N, N-dimethylacetamide/purified water mixed solution and anhydrous methanol, performing throw filtration until no liquid flows out, and collecting the filter cakes;
and 5: adding the filter cake obtained in the step (4) and anhydrous methanol into a reactor, starting stirring, controlling the temperature to be 20-30 ℃, keeping the temperature and stirring for 1h, performing filtration in a throwing manner, leaching the filter cake for 1 time by using the anhydrous methanol, performing filtration in a throwing manner until no liquid flows out, collecting the filter cake, putting the filter cake into a vacuum drier, drying for 5h at the temperature of 55-65 ℃ under the condition that the vacuum degree is more than or equal to 0.09MPa, collecting and weighing to obtain (R) -3- [4- [2- (2-methyltetrazol-5-yl) pyridine-5-yl ] -3-fluorophenyl ] -5-hydroxymethyl oxazolidine;
step three: adding (R) -3- [4- [2- (2-methyltetrazol-5-yl) pyridine-5-yl ] -3-fluorophenyl ] -5-hydroxymethyl oxazolidine, triethylamine and tetrahydrofuran into a reactor under the protection of nitrogen, starting stirring, cooling to-5-5 ℃, adding phosphorus oxychloride/tetrahydrofuran solution, controlling the temperature to-5-5 ℃ after the addition is finished, stirring for 5 hours, taking out the mixed solution, adding purified water into the reactor, cooling to 0-10 ℃, starting stirring, adding the mixed solution, controlling the system temperature to 0-10 ℃ during the addition process, heating to 20-30 ℃ after the addition is finished, stirring for 1 hour, performing swing filtration, leaching a filter cake for 1 time by using purified water, performing swing filtration until no liquid flows out, collecting a filter cake; and (3) putting the filter cake into a reactor, adding methanol and purified water, keeping the temperature, stirring for 0.5h, performing spin filtration, leaching the filter cake for 1 time by using methanol, performing spin filtration until no liquid flows out, collecting the filter cake, putting the filter cake into a hot air circulation drying box, heating to 35-45 ℃, and drying for 4h to obtain the tedizolid phosphate.
The preparation method of the high-purity tedizolid phosphate comprises the following steps of:
4.3 parts of 2-methyl-5- (5-bromopyridine-2-yl) tetrazole, 5.4 parts of pinacol diboron, 3.5 parts of potassium acetate, 35 parts of 1, 4-dioxane and 0.29 part of tetrakis (triphenylphosphine) palladium.
The preparation method of the high-purity tedizolid phosphate comprises the following steps of:
pinacol borate 3.8 parts, (5R) -3- (4-bromo-3-fluorophenyl) -5-hydroxymethyloxazolidine-2-one 4.7 parts, 1, 4-dioxane 24.3 parts, potassium carbonate solution 13.8 parts, tetrakis (triphenylphosphine) palladium 0.67 part, L-cysteine 1.4 parts, triethylamine 1.4 parts.
The preparation method of the high-purity tedizolid phosphate comprises the following steps of:
1 part of (R) -3- [4- [2- (2-methyltetrazol-5-yl) pyridin-5-yl ] -3-fluorophenyl ] -5-hydroxymethyl oxazolidine, 0.82 part of triethylamine, 17.8 parts of tetrahydrofuran and 2.14 parts of phosphorus oxychloride/tetrahydrofuran solution.
In the preparation method of high-purity tedizolid phosphate, the mass ratio of the solute to the solvent of the potassium carbonate solution in the second step is 4.5: 9.3.
According to the preparation method of the high-purity tedizolid phosphate, the N, N-dimethylacetamide/purified water mixed solution is prepared by mixing N, N-dimethylacetamide and purified water according to the mass ratio of 1: 1.
According to the preparation method of the high-purity tedizolid phosphate, the phosphorus oxychloride/tetrahydrofuran solution is prepared by mixing and dissolving phosphorus oxychloride and tetrahydrofuran according to the mass ratio of 1.26: 0.88.
The preparation method of the high-purity tedizolid phosphate, wherein in the first step, the mass of the n-heptane added into the reactor is not more than the mass of the reaction liquid;
in the preparation method of the high-purity tedizolid phosphate, the mass of the n-heptane for washing the filter cake in the first step is not more than that of the filter cake.
In the preparation method of high-purity tedizolid phosphate, the mass of the purified water added into the reactor in the step 1 of the step two is not more than that of the reaction liquid;
according to the preparation method of the high-purity tedizolid phosphate, in the step 1 of the step two, the mass of 1, 4-dioxane of the filter cake washed is not more than that of the filter cake;
in the preparation method of the high-purity tedizolid phosphate, the mass of the N, N-dimethylacetamide added into the reactor together with the filter cake in the step 2 of the step two is 1-4 times of the mass of the filter cake;
in the preparation method of high-purity tedizolid phosphate, the mass of the N, N-dimethylacetamide for washing the filter cake in the step 2 of the second step is not more than that of the filter cake;
in the preparation method of high-purity tedizolid phosphate, the mass of the N, N-dimethylacetamide for washing the filter cake in the step 3 of the step two is not more than that of the filter cake;
in the preparation method of high-purity tedizolid phosphate, the mass of the N, N-dimethylacetamide/purified water mixed solution and the anhydrous methanol for leaching the filter cake in the step 4 of the step two is not more than that of the filter cake;
in the preparation method of the high-purity tedizolid phosphate, the mass of the anhydrous methanol added into the reactor together with the filter cake in the step 5 of the step two is 1-4 times of the mass of the filter cake;
in the preparation method of the high-purity tedizolid phosphate, the mass of the anhydrous methanol for washing the filter cake in the step 5 of the step two is not more than that of the filter cake.
The method for preparing high-purity tedizolid phosphate comprises the following steps that in the third step, the mass of purified water added into the reactor together with the reaction liquid is 0.8-1.5 times of the mass of the reaction liquid;
in the preparation method of the high-purity tedizolid phosphate, the mass of the purified water for washing the filter cake for the first time in the third step is not more than that of the filter cake;
the method for preparing high-purity tedizolid phosphate comprises the following steps that in the third step, the mass of the purified water added into the reactor together with the filter cake is not more than that of the filter cake, and the weight of the methanol added into the reactor together with the filter cake in the third step is 2-5 times that of the filter cake;
in the preparation method of the high-purity tedizolid phosphate, the mass of the methanol in the filter cake rinsed for the second time in the third step is not more than that of the filter cake.
The invention has the advantages that: the process method reported by the invention firstly provides that 2-methyl-5- (5-bromopyridine-2-yl) tetrazole (a compound shown as a formula 1 in a figure 1) is used as a starting material, tetrakis (triphenylphosphine) palladium (Pd (PPh3) 4) is used as a catalyst, bromine of the compound shown as the formula 1 is reacted with pinacol diboron (a compound shown as a formula 2 in the figure 1) to generate pinacol borate (a compound shown as a formula 3 in the figure 1), the bromine is converted into pinacol borate, and the pinacol borate is subjected to Suzuki coupling with (5R) -3- (4-bromo-3-fluorophenyl) -5-hydroxymethyl oxazolidine-2-one (a compound shown as a formula 4 in the figure 1) under the catalytic action of tetrakis (triphenylphosphine) palladium (Pd (PPh3)4 to obtain (R) -3- [4- [2- (2-methyltetrazol-5-yl) pyridine -5-yl ] -3-fluorophenyl ] -5-hydroxymethyl oxazolidine (compound of formula 5 in figure 1), (R) -3- [4- [2- (2-methyltetrazol-5-yl) pyridin-5-yl ] -3-fluorophenyl ] -5-hydroxymethyl oxazolidine is prepared to tedizolid phosphate (compound of formula 6 in figure 1) by phosphatization.
The process method for preparing tedizolid phosphate has the advantages of no need of ultralow temperature operation and simple reaction; the purity is high and can reach more than 95 percent; the by-products are few, and the yield is high and is higher than 70%; the process is stable and has strong operability, avoids high-toxicity organic tin reagents and harsh reaction conditions, also avoids high-risk processes such as hydrogenation reaction and the like, and can realize safe industrial production.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings needed to be used in the description of the embodiments or the prior art will be briefly introduced below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to these drawings without creative efforts.
FIG. 1 is a reaction scheme of the present invention;
FIG. 2 is a purity detection spectrum of doxazosin phosphate.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are some, but not all, embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
A preparation method of high-purity tedizolid phosphate is characterized by comprising the following steps: comprises the following steps:
the method comprises the following steps: adding 2-methyl-5- (5-bromopyridine-2-yl) tetrazole, 5.4kg pinacol diboron, 3.5kg potassium acetate and 35.0kg1, 4-dioxane into a reactor, starting stirring, replacing with nitrogen twice, adding 0.29kg palladium tetrakis (triphenylphosphine) under the protection of nitrogen, heating to 70 ℃, reacting for 4 hours, stopping heating after the reaction is finished, adding 22.0kg n-heptane, cooling to 5 ℃, keeping the temperature and stirring for 1 hour, removing the protection of nitrogen, discharging and pumping, leaching a filter cake once by using 4.0kg n-heptane, pumping and filtering until no filtrate drips, collecting the filter cake, drying at 50 ℃ in a vacuum drying oven, weighing after 8 hours, and obtaining the pinacol borate;
step two:
step 1: adding 3.8kg of pinacol borate, 4.7kg of (5R) -3- (4-bromo-3-fluorophenyl) -5-hydroxymethyl oxazolidine-2-one, 24.3kg of 1, 4-dioxane and 13.8kg of potassium carbonate solution into a reactor, starting stirring, replacing with nitrogen twice, adding 0.67kg of tetrakis (triphenylphosphine) palladium under the protection of nitrogen, heating to 60 ℃, reacting for 5 hours, removing nitrogen after the reaction is finished, cooling to 25 ℃, adding 9.3kg of purified water, cooling to 10 ℃, keeping the temperature, stirring for 0.5 hour, performing spin filtration, leaching a filter cake with 4.7kg of 1 and 4-dioxane for 1 time, performing spin filtration until no liquid flows out, and collecting the filter cake;
step 2: adding the filter cake obtained in the step (1) and 55.0kg of N, N-dimethylacetamide into a reactor, starting stirring, heating to 60 ℃, keeping the temperature and stirring for 1h, cooling to 20 ℃, filtering, leaching the filter cake with 4.3kg of N, N-dimethylacetamide, and collecting filtrate;
and step 3: adding the filtrate obtained in the step (2), 1.4 kgL-cysteine and 1.4kg triethylamine into a reactor, starting stirring, reacting in a dark place, replacing with nitrogen once, heating to 60 ℃, reacting for 16h, cooling to 20 ℃, reacting for 0.5h, performing suction filtration, leaching the filter cake with 13.0kgN, N-dimethylacetamide for 1 time, and collecting the filtrate;
and 4, step 4: adding the filtrate obtained in the step 3 into a reactor, starting stirring, cooling to 10 ℃, adding purified water, controlling the temperature at 15 ℃ in the process of adding the purified water, stirring for 1h at the temperature of 20 ℃, performing throw filtration, leaching a filter cake for 1 time by using 4.7kg of N, N-dimethylacetamide/purified water mixed solution and 3.7kg of anhydrous methanol respectively, and collecting the filter cake until no liquid flows out;
and 5: adding the filter cake obtained in the step (4) and 55.0kg of anhydrous methanol into a reactor, starting stirring, controlling the temperature to be 25 ℃, keeping the temperature and stirring for 1h, performing filter throwing, leaching the filter cake for 1 time by using 18.0kg of anhydrous methanol, performing filter throwing until no liquid flows out, collecting the filter cake, putting the filter cake into a vacuum drier, drying for 5h at the temperature of 60 ℃ under the condition that the vacuum degree is more than or equal to 0.09MPa, collecting and weighing to obtain (R) -3- [4- [2- (2-methyltetrazol-5-yl) pyridin-5-yl ] -3-fluorophenyl ] -5-hydroxymethyl oxazolidine;
step three: adding 1.0kg of (R) -3- [4- [2- (2-methyltetrazol-5-yl) pyridine-5-yl ] -3-fluorophenyl ] -5-hydroxymethyl oxazolidine, 0.32kg of triethylamine and 17.8kg of tetrahydrofuran into a reactor under the protection of nitrogen, starting stirring, cooling to 0 ℃, slowly adding 2.14kg of phosphorus oxychloride/tetrahydrofuran solution, controlling the temperature to 0 ℃ after the addition is finished, stirring for reacting for 5 hours, taking out the mixed solution, adding 20.0kg of purified water into the reactor, cooling to 5 ℃, starting stirring, adding the mixed solution, controlling the temperature of the system in the feeding process to 5 ℃, controlling the temperature to 25 ℃ after the addition is finished, stirring for 1 hour, performing swing filtration, leaching a filter cake for 1 time by using 1.0kg of purified water, performing the swing filtration until no liquid flows out, and collecting the filter cake; and (2) putting the filter cake into a reactor, adding 5.9kg of methanol and 0.7kg of purified water, keeping the temperature, stirring for 0.5h, performing spin filtration, leaching the filter cake for 1 time by using 0.7kg of methanol, performing spin filtration until no liquid flows out, collecting the filter cake, putting the filter cake into a hot air circulation drying box, heating to 40 ℃, and drying for 4h to obtain the tedizolid phosphate, wherein the calculated yield is 75.68% and the purity is 99.95%.
The yield and the purity of the tedizolid phosphate prepared by the method are higher than those of the tedizolid phosphate prepared by the existing preparation method, the operation is simple, the process is stable, the operability is strong, high-toxicity organic tin reagents and harsh reaction conditions are avoided, high-risk processes such as hydrogenation reaction and the like are also avoided, and the safe industrial production can be realized.
Finally, it should be noted that: the above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911241003.3A CN111116652A (en) | 2019-12-06 | 2019-12-06 | A kind of preparation method of high-purity tedizolid phosphate |
CN202010525619.XA CN111518135B (en) | 2019-12-06 | 2020-06-10 | A kind of preparation method of high-purity tedizolid phosphate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911241003.3A CN111116652A (en) | 2019-12-06 | 2019-12-06 | A kind of preparation method of high-purity tedizolid phosphate |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111116652A true CN111116652A (en) | 2020-05-08 |
Family
ID=70497634
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911241003.3A Pending CN111116652A (en) | 2019-12-06 | 2019-12-06 | A kind of preparation method of high-purity tedizolid phosphate |
CN202010525619.XA Expired - Fee Related CN111518135B (en) | 2019-12-06 | 2020-06-10 | A kind of preparation method of high-purity tedizolid phosphate |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010525619.XA Expired - Fee Related CN111518135B (en) | 2019-12-06 | 2020-06-10 | A kind of preparation method of high-purity tedizolid phosphate |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN111116652A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113214239A (en) * | 2021-04-06 | 2021-08-06 | 海南通用康力制药有限公司 | Tedizolid refining process and preparation method of tedizole phosphate |
CN114105968A (en) * | 2020-08-28 | 2022-03-01 | 河北明吉化工科技有限公司 | Method for removing palladium residue of tedizolid |
CN115385959A (en) * | 2022-09-27 | 2022-11-25 | 浙江尖峰药业有限公司 | High-purity tedizolid phosphate and preparation method thereof |
CN115873036A (en) * | 2022-09-30 | 2023-03-31 | 中国药科大学 | Synthetic method of tedizolid phosphate |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112500433A (en) * | 2020-12-23 | 2021-03-16 | 桂林南药股份有限公司 | Preparation method of tedizolid phosphate |
CN115246828A (en) * | 2021-04-28 | 2022-10-28 | 苏州朗科生物技术股份有限公司 | Palladium removal method for tedizolid phosphate intermediate |
CN114315898B (en) * | 2021-12-31 | 2024-01-12 | 山西振东泰盛制药有限公司 | Preparation method of tedizolid phosphate and intermediate thereof, and injection |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106220621B (en) * | 2008-10-10 | 2019-06-11 | 默沙东公司 | Prepare the method for oxazolidinones and the composition containing oxazolidinones |
CN104496979A (en) * | 2014-09-17 | 2015-04-08 | 博瑞生物医药技术(苏州)有限公司 | Method for preparing oxazolidinone compound and intermediate thereof |
CN105418678B (en) * | 2014-09-17 | 2018-11-20 | 正大天晴药业集团股份有限公司 | A kind of preparation method of Tedizolid Phosphate |
CN105985331A (en) * | 2015-02-02 | 2016-10-05 | 上海医药工业研究院 | Process for preparing tedizolid |
CN104892592A (en) * | 2015-03-30 | 2015-09-09 | 成都惟新医药科技有限公司 | Preparation method for tedizolid |
CN106146485B (en) * | 2015-04-01 | 2021-04-30 | 上海迪赛诺化学制药有限公司 | Method for preparing tedizolid and tedizolid crystal obtained by method |
CN105131037B (en) * | 2015-07-28 | 2017-05-03 | 济南爱思医药科技有限公司 | Preparation method for high-purity tedizolid phosphate |
CN106632298B (en) * | 2015-11-03 | 2021-06-01 | 上海科胜药物研发有限公司 | Preparation method and intermediate of tedizolid |
CN105418681A (en) * | 2015-12-15 | 2016-03-23 | 南京艾德凯腾生物医药有限责任公司 | Preparation method of tedizolid phosphate |
CN107382995A (en) * | 2017-09-01 | 2017-11-24 | 杭州新博思生物医药有限公司 | One pot process safe ground azoles amine |
-
2019
- 2019-12-06 CN CN201911241003.3A patent/CN111116652A/en active Pending
-
2020
- 2020-06-10 CN CN202010525619.XA patent/CN111518135B/en not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114105968A (en) * | 2020-08-28 | 2022-03-01 | 河北明吉化工科技有限公司 | Method for removing palladium residue of tedizolid |
CN114105968B (en) * | 2020-08-28 | 2024-04-16 | 河北明吉化工科技有限公司 | Method for removing residual palladium of tedizolid |
CN113214239A (en) * | 2021-04-06 | 2021-08-06 | 海南通用康力制药有限公司 | Tedizolid refining process and preparation method of tedizole phosphate |
CN113214239B (en) * | 2021-04-06 | 2023-04-07 | 海南通用康力制药有限公司 | Tedizolid refining process and preparation method of tedizole phosphate |
CN115385959A (en) * | 2022-09-27 | 2022-11-25 | 浙江尖峰药业有限公司 | High-purity tedizolid phosphate and preparation method thereof |
CN115873036A (en) * | 2022-09-30 | 2023-03-31 | 中国药科大学 | Synthetic method of tedizolid phosphate |
Also Published As
Publication number | Publication date |
---|---|
CN111518135B (en) | 2022-05-06 |
CN111518135A (en) | 2020-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111518135B (en) | A kind of preparation method of high-purity tedizolid phosphate | |
CN105968032B (en) | The synthetic method of Metformin hydrochloride | |
CN101318914A (en) | Method for preparing urea phosphoric acid with wet-process phosphoric acid | |
CN104086539A (en) | Preparation method of rivaroxaban | |
CN104829495B (en) | A kind of method that two-component solvent prepares high-purity high-yield Metformin hydrochloride | |
CN104119250A (en) | Production method of high-purity metformin hydrochloride | |
CN107011205A (en) | A kind of method for producing large-grain occrycetin | |
CN110698467B (en) | Synthesis method of englitjing | |
CN109651177A (en) | Preparation method of benzethonium chloride | |
CN108033903B (en) | Synthesis process for water-borne esterification of DL-p-methylsulfonylphenylserine ethyl ester | |
CN101014601B (en) | Preparation of 9-hydroxy-3- (2-hydroxyethyl) -2-methyl-4h-pyrid0[1, 2-a] pyrimidin-4-one and crystals thereof | |
CN102321068B (en) | Method for preparing strontium ranelate | |
CN108164530A (en) | A kind of environmentally friendly process for purification of theobromine | |
CN108017553A (en) | The preparation method of methacetin | |
CN103709174B (en) | The one-step synthesis of the bromo-3H-oxazole of 6-also [4,5-b] pyridin-2-ones | |
CN105753733A (en) | AHU377 crystal form and preparation method and uses thereof | |
CN104513251A (en) | Nalmefene hydrochloride preparation method | |
CN107722056A (en) | The preparation method of Tedizolid Phosphate | |
CN107698498A (en) | A kind of preparation method of oxycodone | |
CN102206185B (en) | Process for refining bendazac lysine and analogs thereof | |
CN113336791A (en) | Production method of fosfomycin calcium bulk drug | |
CN106928193B (en) | Preparation meets the method for the esomeprazole magnesium trihydrate of standards of pharmacopoeia | |
CN103910695B (en) | A kind of synthetic method of Febuxostat | |
CN112375030B (en) | Preparation method of diphenoxylate hydrochloride | |
CN109851563A (en) | A kind of preparation method of the biphenol monomer containing naphthyridine ketone structure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200508 |